Technetium-99m-sestamibi uptake in myeloma.

A number of reports describe how 99m Tc-sestamibi detects benign and malignant primary and metastatic tumors. We report abnormal 99m Tc-sestamibi uptake in nine sites in a 53-yr-old patient with histologically and biochemically proven IgG kappa-secreting myeloma. The 99m Tc-sestamibi study was undertaken for an unrelated hyperparathyroidism.